Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Non-Adherence to Prescribed Antihypertensives in Primary, Secondary and Tertiary Healthcare Settings in Islamabad, Pakistan: A Cross-Sectional Study.

Tytuł :
Non-Adherence to Prescribed Antihypertensives in Primary, Secondary and Tertiary Healthcare Settings in Islamabad, Pakistan: A Cross-Sectional Study.
Autorzy :
Mahmood S; Department of Pharmacy, Quaid-e-Azam University, Islamabad 45320, Pakistan.
Jalal Z; School of Pharmacy, College of Medical and Dental Sciences, Institute of Clinical Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Hadi MA; School of Pharmacy, College of Medical and Dental Sciences, Institute of Clinical Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Orooj H; Directorate of Health Services, Metropolitan Corporation Islamabad, Islamabad, Pakistan.
Shah KU; Department of Pharmacy, Quaid-e-Azam University, Islamabad 45320, Pakistan.
Pokaż więcej
Źródło :
Patient preference and adherence [Patient Prefer Adherence] 2020 Jan 14; Vol. 14, pp. 73-85. Date of Electronic Publication: 2020 Jan 14 (Print Publication: 2020).
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Original Publication: [Auckland, N.Z.] : Dove Press Limited
References :
J Ayub Med Coll Abbottabad. 2008 Apr-Jun;20(2):66-9. (PMID: 19385461)
J Epidemiol Glob Health. 2015 Jun;5(2):125-32. (PMID: 25922321)
Int J Clin Pract. 2008 Jan;62(1):76-87. (PMID: 17983433)
J Hum Hypertens. 2006 Apr;20(4):295-7. (PMID: 16424861)
Int J Epidemiol. 2017 Apr 1;46(2):589-602. (PMID: 27864410)
Acta Med Indones. 2005 Jan-Mar;37(1):20-5. (PMID: 15986551)
Nephrourol Mon. 2015 Jul 30;7(4):e29863. (PMID: 26539419)
N Engl J Med. 2017 Aug 24;377(8):733-744. (PMID: 28834483)
Patient Educ Couns. 2015 May;98(5):669-73. (PMID: 25746128)
Curr Hypertens Rep. 2015 Dec;17(12):94. (PMID: 26560139)
Patient Prefer Adherence. 2019 Jan 11;13:119-129. (PMID: 30666095)
J Hum Hypertens. 2017 Jan;31(1):14-21. (PMID: 27306087)
Blood Press Suppl. 2005 Dec;2:46-9. (PMID: 16429643)
Medicine (Baltimore). 2016 May;95(20):e3572. (PMID: 27196458)
Patient Prefer Adherence. 2012;6:127-35. (PMID: 22379363)
Prim Care Diabetes. 2018 Apr;12(2):116-125. (PMID: 29170095)
J Pak Med Assoc. 2002 Apr;52(4):174-82. (PMID: 12174483)
PLoS One. 2014 Jan 15;9(1):e84238. (PMID: 24454721)
Eur J Hosp Pharm. 2016 Sep;23(5):250-256. (PMID: 31156861)
CMAJ. 1999 Jan 12;160(1):31-7. (PMID: 9934341)
Int J Cardiol. 2015 Mar 1;182:250-7. (PMID: 25585359)
J Clin Pharmacol. 1996 Aug;36(8):674-82. (PMID: 8877670)
Hypertension. 2015 Aug;66(2):254-9. (PMID: 26077565)
Arch Public Health. 2018 Apr 2;76:20. (PMID: 29619218)
PLoS One. 2013 Apr 25;8(4):e62775. (PMID: 23638143)
East Mediterr Health J. 2002 Jul-Sep;8(4-5):579-92. (PMID: 15603041)
Value Health. 2013 Jul-Aug;16(5):863-71. (PMID: 23947982)
Curr Opin Cardiol. 2004 Jul;19(4):357-62. (PMID: 15218396)
Clin Pharmacol Ther. 2000 Dec;68(6):586-91. (PMID: 11180017)
J Hum Hypertens. 2006 Jan;20(1):23-9. (PMID: 16177812)
J Gen Intern Med. 2015 Apr;30(4):469-75. (PMID: 25500787)
J Clin Epidemiol. 2011 Mar;64(3):255-7; discussion 258-63. (PMID: 21144706)
Int J Clin Pharm. 2019 Feb;41(1):122-130. (PMID: 30564971)
Trials. 2016 Mar 05;17(1):121. (PMID: 26944938)
PLoS One. 2017 Jan 30;12(1):e0171255. (PMID: 28135324)
Patient Prefer Adherence. 2018 Oct 17;12:2205-2216. (PMID: 30410316)
Salud Publica Mex. 2001 Jul-Aug;43(4):336-9. (PMID: 11547594)
Am J Manag Care. 2011 Dec;17(12 Spec No.):SP79-87. (PMID: 22216772)
BMC Res Notes. 2017 Dec 4;10(1):668. (PMID: 29202794)
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54. (PMID: 18453793)
Lancet. 2014 May 31;383(9932):1899-911. (PMID: 24881994)
PLoS One. 2007 Mar 14;2(3):e280. (PMID: 17356691)
Hypertension. 2009 Mar;53(3):450-1. (PMID: 19204176)
Am J Public Health. 1996 Dec;86(12):1805-8. (PMID: 9003143)
Ther Clin Risk Manag. 2008 Feb;4(1):269-86. (PMID: 18728716)
Med Care. 1986 Jan;24(1):67-74. (PMID: 3945130)
Lancet. 2017 Dec 9;390(10112):2549-2558. (PMID: 29102084)
PLoS Med. 2019 May 3;16(5):e1002801. (PMID: 31050680)
Contributed Indexing :
Keywords: Asia; Pakistan; adherence; antihypertensives; blood pressure control; cross-sectional study; hypertension
Entry Date(s) :
Date Created: 20200206 Latest Revision: 20200928
Update Code :
20210914
PubMed Central ID :
PMC6969702
DOI :
10.2147/PPA.S235517
PMID :
32021119
Czasopismo naukowe
Objective: This study aimed to assess the prevalence and predictors of non-adherence to antihypertensive medication among patients with hypertension attending various healthcare settings in Islamabad, Pakistan.
Methods: A questionnaire-based cross-sectional study was conducted in selected healthcare facilities between September 2017 and December 2018. The study was conducted in primary, secondary and tertiary healthcare settings in Islamabad, Pakistan. Medication adherence was assessed using the eight-item Morisky Medication Adherence Scale (MMAS-8). Sociodemographic and clinical data of recruited patients were collected through a structured questionnaire. Binary logistic regression analysis was performed to determine covariates significantly associated with medication adherence and blood pressure control.
Results: A total of 776 hypertensive patients were invited and 741 (95%) completed the questionnaire. The mean ± SD age of participants was 53.6±12.6 years; 284 patients (38.3%) had high adherence, 178 (24%) had moderate adherence and 279 (37.7%) were non-adherent to the prescribed antihypertensive therapy. Binary regression analysis revealed that old age (OR 1.783 [95% CI: 1.172-2.712]; P =0.013), being educated (OR 2.018 [95% CI: 1.240-3.284]; P =0.036), entitlement to free medical care (OR 1.369 [95% CI: 1.009-1.859]; P =0.044), treatment duration (OR 2.868 [95% CI: 1.913-4.299]; P =0.001), number of medications (OR 1.973 [95% CI: 1.560-2.495]; P =0.001), presence of any comorbidity (OR 2.658 [95% CI: 1.836-3.848]; P =0.001) and blood pressure control (OR 3.103 [95% CI: 2.268-4.247]; P =0.001) were significantly associated with good adherence. Similarly, age (OR 1.998 [95% CI: 1.313-3.040]; P =0.004), entitlement to free medical care (OR 1.498 [95% CI: 1.116-2.010]; P =0.007), treatment duration (OR 1.886 [95% CI: 1.143-3.113]; P =0.013), presence of any comorbidity (OR 1.552 [95% CI: 1.123-2.147]; P =0.008) and adherence level (OR 3.103 [95% CI: 2.268-4.247]; P =0.001) had significant association with controlled blood pressure. The following were the main reasons for non-adherence to prescribed antihypertensive medication: "don't feel need for regular use" (24.7%), "Carelessness" (13.4%) and "adverse effects" (11.2%).
Conclusion: The prevalence of non-adherence to antihypertensive medications was high in the study population and poor medication adherence could potentially explain poor blood pressure control. Evidence-based targeted interventions on both medication adherence and blood pressure control should be introduced and implemented for better treatment outcomes.
(© 2020 Mahmood et al.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies